Therapie von Patienten mit Retroperitonealen Sarkomen (RPS): Daten aus der prospektiven PROSa-Studie im Vergleich zu internationalen Sarkomzentren und Umfrageergebnissen aus deutschen chirurgischen Kliniken

by Inga Annette Kreisel
Doctoral thesis
Date of Examination:2023-01-31
Date of issue:2023-01-19
Advisor:Prof. Dr. Jens Jakob
Referee:PD Dr. Annemarie Uhlig
Referee:Prof. Dr. Ralf Dressel
Persistent Address: http://dx.doi.org/10.53846/goediss-9671

 

 

Files in this item

Name:Therapie von Patienten mit Retroperitonealen...pdf
Size:1009Kb
Format:PDF

The following license files are associated with this item:

Abstract

English

Background: Retroperitoneal sarcomas are very rare tumours (incidence 0,5 - 1/100.000/year) with more than 50 histological subtypes. The most common subtypes are liposarcomas (LPS), leiomyosarcomas (LMS)m solitary fibrous tumours and malignant peripheral nerve sheath tumours. First line therapy is the surgical resection, the role of chemotherapy and radiation is still indistinct. Also there are less informations about des quality of life (QoL) about patients with RPS. In our study we want to reveal the aspects of QoL of patients with RPS with our subgroup analysis by using datas of the PROSa-study. Additionally we want to prove the representation of the patient´s characteristics and the comparability of the therapy on international level. At last we want to compare the assumption in regard to the diagnostics an therapy of RPS from the dates of the DGAV-survey an the actually situation by reference of the PROSa results. Methods: 263 patients with RPS were identified from the PROSa-study (124 female, 139 male). We structured our subgroup analysis to our main focus: inquiry the QoL and analysis of diagnostics and therapy of RPS. Therefor we extracted treatment data of our PROSa results and compared it with similary data of the TARPSWG results and the DGAV-survey. Results: Our results are comparable with the TARPSWG (epidemiology, local recurrence, metastasis and therapy) while there are clear differences to the results from the DGAV survey. The main restrictions in QoL we found for physical und cognitive functioning. Overall patients with RPS assess QoL only moderate. Conclusions: Especially physical and cognitive functioning of patients with RPS are affected. Our results are comparable with international data (TARPSWG vs. PROSa) regarding diagnostics and therapy so we can proceed from representative cohort in our study. At the national level there is a clear discrepancy between supposed therapy algorism and truly realised therapy.
Keywords: retroperitoneal sarcoma; quality of life; therapy; diagnostics
 
Statistik